Naweed & Kamran Research
October 13, 2022
GoodRx’s revenue for the third quarter decreased 4% year-over-year to $187.3 million, exceeding the guidance provided by the company. Prescription transactions revenue decreased 16% year-over-year to $131.2 million due to the grocer issue. However, the issue has now been resolved and consumers can once again get GoodRx (GDRX) discounts with the grocer. Disappointed by its year to date performance, GoodRx (GDRX) is …..
Overview of Segments’ Performance
Since its inception, GoodRx (GDRX) platform was aimed at providing users with meaningful savings without creating an account. As the company now intends to play a more active role in all aspects of its customers’ health care and diversify its revenue, GoodRx (GDRX) is requiring its users to register in the GoodRx Platform. This is expected to affect the revenue negatively. GoodrRx’s total revenue guidance for the third quarter reflects a year-over-year decline in revenue, with the grocer issue and the company’s registration efforts negatively impacting their year-over-year growth rates by more than …..
Although the grocer issue has been resolved, GoodRx (GDRX) does not expect a meaningful volume or revenue increase in the third quarter due to the rollout timeline of relevant communications to the grocery chain’s pharmacies, new user adoption and returning user levels. The company expects its third quarter revenue to be approximately …..
GoodRx has successfully completed a number of strategic acquisitions in the past, including Sappira, FocusScript, Scriptcycle, HealthiNation, RxSaver, RxNXT, and flipMD.
In the second quarter GoodRx acquired vitaCare, a pharmacy services platform that gives GoodRx valuable capabilities to facilitate the brand location prescription process from start to finish, enhancing the company’s pharma focus capabilities.
Moreover, GoodRx has announced a strategic initiative with Mayne Pharma to deliver an enhanced direct-to-consumer campaign that aims to bring broader awareness and access to a novel contraceptive NEXTSTELLIS and other available birth control options to consumers, as well as build awareness among healthcare providers. This initiative demonstrates the tremendous …..